Zanubrutinib
- CAS No.
- 1691249-45-2
- Chemical Name:
- Zanubrutinib
- Synonyms
- Zebutinib;anubrutinib;Zanubrutinib;Zanmubrutinib;Zanubtutinib AP;Zanubrutinib API;The BTK inhibitor;BGB-3111(Zanubrutinib);Zanubrutinib (BGB-3111);Zanubrutinib API & all impurites
- CBNumber:
- CB93361383
- Molecular Formula:
- C27H29N5O3
- Molecular Weight:
- 471.55
- MOL File:
- 1691249-45-2.mol
- Modify Date:
- 2024/7/2 8:55:42
| Boiling point | 713.4±60.0 °C(Predicted) |
|---|---|
| Density | 1.33±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility |
DMSO:99.67(Max Conc. mg/mL);211.36(Max Conc. mM) DMF:10.0(Max Conc. mg/mL);21.21(Max Conc. mM) DMF:PBS (pH 7.2) (1:5):0.16(Max Conc. mg/mL);0.34(Max Conc. mM) Ethanol:33.33(Max Conc. mg/mL);70.68(Max Conc. mM) |
| form | A solid |
| pka | 15.35±0.40(Predicted) |
| color | White to off-white |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P305+P351+P338 | |||||||||
| NFPA 704 |
|
Zanubrutinib Chemical Properties,Uses,Production
Description
Zanubrutinib, a second-generation BTK inhibitor discovered and developed by BeiGene in China, has been approved by the FDA (in 2019) for treating chronic lymphocytic leukemia (CLL) and certain other indications. Zanubrutinib has lower toxicity and better efficacy than ibrutinib. It is in direct competition with AstraZeneca’s acalabrutinib for the $12 billion blood cancer market currently dominated by the first-in-class BTK inhibitor ibrutinib.
Uses
Zanubrutinib is classified as a Bruton''s tyrosine kinase inhibitor. Zanubrutinib is a medication for the treatment of adults with mantle cell lymphoma.
brand name
BrukinsaTM
General Description
Class: non-receptor tyrosine kinase
Treatment: MCL, MZL, WM
Oral bioavailability = 15%
Elimination half-life = 3.3 h
Protein binding = 94%
target
BTK
Metabolism
Zanubrutinib showed a mean terminal elimination half-life of approximately 2–4 h (160 or 320 mg, QD) and an estimated oral bioavailability of 15%, relative to 3.9% (fasting state) for ibrutinib. Zanubrutinib is primarily eliminated hepatically via CYP3A4, but its metabolites have not been characterized.
Zanubrutinib Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| CHEMAZON LABORATORIES | +91 9848551964 | Hyderabad, India | 1320 | 58 | Inquiry |
| Venkatasai Life Sciences | +91-9908134868 +91-8008303069 | Hyderabad, India | 186 | 58 | Inquiry |
| ARRKEM LIFE SCIENCES PRIVATE LIMITED | +91-8148739767 +91-8148739767 | Telangana, India | 260 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
| Pharma Affiliates | 172-5066494 | Haryana, India | 6761 | 58 | Inquiry |
| Jinan Jianfeng Chemical Co., Ltd | 0531-88110457; +8615562555968 | China | 225 | 58 | Inquiry |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | China | 32760 | 60 | Inquiry |
| Shenzhen Nexconn Pharmatechs Ltd | +86-755-89396905 +86-15013857715 | China | 10259 | 58 | Inquiry |
Related articles
- How to synthesize Zanubrutinib?
- Zanubrutinib is a drug that was shown to effectively treat cancer of B cells without causing severe excessive side effects.
- Jan 25，2024
1691249-45-2(Zanubrutinib)Related Search:
1of4
chevron_right